{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"24.8","value":"3.55"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"68.9","value":"3.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Time to objective response is defined as the time from randomization to first response (complete response, CR or partial response, PR). CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR=At least a 30% decrease in the sum of diameters of target lesions, the baseline sum diameters used as reference.","dispersionType":"Full Range","groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG001","title":"Everolimus"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with a response; any participants that was randomized to any treatment group in the study and that had a response.","reportingStatus":"POSTED","timeFrame":"Randomization to date of first response (approximately 105 months)","title":"Investigator-assessed Time to Objective Response","type":"SECONDARY","unitOfMeasure":"months"}